Unusual expansion of CD3+CD56+ natural killer T-like cells in peripheral blood after anticytokine treatment for graft-versus-host disease: A case report

RATIONALE: Basiliximab and etanercept have achieved promising responses in steroid-refractory graft versus host disease (SR-GVHD). However, the in vivo immune changes following the treatment have not been elucidated. PATIENT CONCERNS: A 14-year-old boy presented with skin rash and diarrhea 20 days a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Lixia, Fu, Huarui, Tan, Yamin, Hu, Yongxian, Mu, Qitian, Luo, Yi, Shi, Jianmin, Cai, Zhen, Ouyang, Guifang, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160206/
https://www.ncbi.nlm.nih.gov/pubmed/30235723
http://dx.doi.org/10.1097/MD.0000000000012429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160206/
https://www.ncbi.nlm.nih.gov/pubmed/30235723
http://dx.doi.org/10.1097/MD.0000000000012429

Ejemplares similares